Bisoprolol Fumarate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Bisoprolol Fumarate: Drug Repurposing Evaluation Report
One-Sentence Summary
Bisoprolol fumarate is a selective beta-1 adrenergic receptor blocker, widely used for hypertension and heart failure management. The TxGNN model did not generate any predicted new indications for this drug in the current analysis cycle. With 34 registrations in Malaysia, the drug has established market presence but requires additional data collection before repurposing assessment can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension, heart failure (license detail unavailable in current data) |
| Predicted New Indication | — (No prediction generated) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No prediction or supporting studies) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 34 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No predicted indication was generated by the TxGNN model for Bisoprolol Fumarate in this analysis round. This may be due to one or more of the following reasons:
-
Missing DrugBank ID mapping: The Evidence Pack shows
drugbank_id: null. Without a valid DrugBank identifier, the drug cannot be properly linked into the TxGNN knowledge graph, preventing the model from generating drug–disease predictions. The query log indicates a DrugBank query was executed with 1 result returned, but the ID was not successfully mapped into the evidence pack. -
Incomplete indication text: All five licence records in the regulatory data have empty
approved_indication_textfields. Without parsed indication information, the system cannot establish the drug’s original therapeutic context or map it to disease nodes in the knowledge graph.
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Bisoprolol is a highly selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker). It reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in cardiac tissue. Its established indications include essential hypertension, chronic stable angina pectoris, and chronic heart failure (as adjunctive therapy). These mechanisms could theoretically be relevant to other cardiovascular or sympathetic nervous system–mediated conditions, but no computational prediction is available to evaluate at this time.
Clinical Trial Evidence
Currently no related clinical trials identified — no predicted indication was generated for evaluation.
Literature Evidence
Currently no related literature identified — no predicted indication was generated for evaluation.
Malaysia Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| (unavailable) | (unavailable) | (unavailable) | (unavailable) |
| (unavailable) | (unavailable) | (unavailable) | (unavailable) |
| (unavailable) | (unavailable) | (unavailable) | (unavailable) |
| (unavailable) | (unavailable) | (unavailable) | (unavailable) |
| (unavailable) | (unavailable) | (unavailable) | (unavailable) |
Note: 34 registrations were retrieved from NPRA, but detailed licence fields (authorization number, product name, dosage form, approved indication) were not populated in the current evidence pack. Re-extraction from the NPRA database is required.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in this evidence pack. As a known beta-blocker, general precautions include avoidance in patients with severe bradycardia, cardiogenic shock, decompensated heart failure, sick sinus syndrome (without pacemaker), severe bronchial asthma, and phaeochromocytoma (without alpha-blocker coverage).
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN prediction was generated for Bisoprolol Fumarate due to critical data gaps — specifically, the missing DrugBank ID mapping and empty licence indication fields. Without a valid knowledge graph linkage, the repurposing prediction pipeline cannot execute. This is a data completeness issue, not a negative signal about the drug’s repurposing potential.
To proceed, the following is needed:
- DrugBank ID resolution (Blocking): Confirm and populate the DrugBank ID (expected: DB01612 for Bisoprolol). The query log shows 1 result was returned — investigate why it was not mapped.
- NPRA licence detail extraction (Blocking): Re-extract the 34 NPRA licence records with complete fields (authorization number, product name, dosage form, approved indication text).
- Mechanism of action (High priority): Retrieve MOA data from DrugBank API to enable mechanism–indication reasoning.
- Safety data (Blocking for S1 assessment): Extract package insert warnings and contraindications from NPRA or product label PDFs.
- Re-run TxGNN prediction: Once DrugBank ID and indication data are populated, re-execute the KG + DL prediction pipeline to generate repurposing candidates.
Disclaimer: This report is for research reference only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.